Business Wire

Xsolla Unveils Cloud Gaming Trials to Convert Game Demos Into Revenue

15.8.2025 15:00:00 CEST | Business Wire | Press Release

Share

Xsolla, a global commerce company helping developers launch, grow and monetize their games, announces today game trials as a new focus for its Cloud Gaming solution. Designed to help developers and publishers boost visibility, player acquisition, and conversion, the upgraded Cloud Gaming solution bridges the gap between marketing and monetization by enabling instant game access, real-time performance tracking, and flexible pay-to-play models.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250815871365/en/

(Graphic: Xsolla)

In an increasingly competitive cloud gaming market projected to surpass $10.4 billion in global revenue by 2025, developers are seeking scalable and cost-effective ways to engage players both before and after launch. With over 19,000 games added to Steam in 2024 alone, visibility and differentiation are more critical than ever. Xsolla’s upgraded Cloud Gaming solution addresses these challenges by offering a frictionless way for players to try games instantly in the browser, while enabling publishers to monetize that engagement through in-stream purchases, game key sales, and direct referrals.

Players can instantly launch a game without downloads or installs with a simple “Play Now” button or deep-link listing on x.la/cloud-gaming. Using our “Play Before You Buy” feature, players can try the game for up to 15 minutes in a cloud-streamed session before deciding to purchase. These trial experiences support pay-as-you-go monetization and full-game purchases through direct key sales, including platforms like Steam, PlayStation, Xbox, Nintendo Switch, and Epic Games, all accessible through the in-stream overlay.

Key benefits of Xsolla Cloud Gaming Trials include:

  • Instant Game Access: One-click browser-based demos with no install required.
  • Flexible Monetization Models: Support for play-before-you-buy, pay-as-you-go, and direct key sales.
  • Publisher Control: Full ownership over data, player journeys, and campaign performance.
  • Marketing Attribution: Real-time tracking of engagement, referral sources, and conversion.
  • Controlled Distribution: Whitelisting tools for media access, VIP demos, or phased campaign launches.
  • Global Reach with Lower Cost: Direct-to-consumer and Xsolla Mall distribution lowers acquisition costs.

“With Cloud Gaming Trials, we’ve created a powerful way to transform marketing campaigns into measurable sales engines,” said Chris Hewish, President at Xsolla. “You no longer need to wait for a wishlist or an install; we’re giving the ability to provide players with instant access to their favorite games while giving developers full control over what happens next.”

Cloud Gaming Trials is ideal for pre-launch community building and post-launch re-engagement. Studios can list demos on Xsolla’s cloud store to drive early interest and conversion. Once live, publishers can use the same tools to enable sampling, track click-through-to-purchase rates, and adjust campaign targeting based on performance. By combining flexible monetization with actionable data, developers can optimize marketing spend and grow their audience more effectively.

Unlike traditional marketplaces where visibility is algorithm-dependent and analytics are limited, Xsolla Cloud Gaming Trials puts discovery and data back in the hands of creators. The platform empowers teams to run whitelisted demos for press, partners, or influencers, enabling targeted promotions without public exposure.

Xsolla invites developers, studios, and publishers to utilize Cloud Gaming Trials to boost conversion, expand player reach, and streamline campaign execution.

To start or list your game on the Xsolla Cloud Store, visit x.la/cloud-gaming or contact the Xsolla Publisher team.

For a complete list of enhancements and developer tools, visit: xsolla.pro/rws25cloudgaming

About Xsolla

Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game.

For more information, visit xsolla.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250815871365/en/

Contacts

Media Contact

Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye